Last reviewed · How we verify
Sildenafil & Vardenafil
Sildenafil and Vardenafil are marketed drugs under Rambam Health Care Campus, with a key composition patent expiring in 2028. The primary strength of these drugs lies in their established market presence and well-documented efficacy. The primary risk is the upcoming patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Sildenafil & Vardenafil |
|---|---|
| Sponsor | Rambam Health Care Campus |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Vardenafil Vs Sildenafil for the Treatment of Pulmonary Hypertension of the Newborn (PHASE1, PHASE2)
- PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) (PHASE4)
- A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
- FDA Phase IV - Commitment - Retinal Function Study (PHASE4)
- Assess the Effect of Daily Treatment of Vardenafil 20mg or Sildenafil 100mg and Placebo on Sperm Function (PHASE4)
- Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction (PHASE3)
- Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i (PHASE4)
- The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |